Skip to content

Clinical Features of COVID-19 Patients

Clinical Features of Severe Acute Respiratory Syndrome Coronavirus 2 Patients Admitted to the Intensive Care Units of Academic Hospital of L'Aquila (Italy)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04815304
Enrollment
200
Registered
2021-03-25
Start date
2020-03-13
Completion date
2023-11-13
Last updated
2023-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Respiratory Distress Syndrome, Covid19, Ventilatory Failure

Brief summary

The data were retrospectively collected during the first and the second wave of epidemic in COVID-19 patients with Severe Acute Respiratory Syndrome Coronavirus 2, at the moment of intensive care unit admission and during the in intensive care unit staying.

Detailed description

At the moment of intensive care unit admission and during the in intensive care unit staying, the following data were collected: peripheral lymphocyte subsets were measured by multiple-color flow cytometry, chest computed tomography and ultrasonography scans, arterial blood gas parameters (pH, partial pressure of carbon dioxide, partial pressure of oxygen, concentration of hydrogen carbonate, base excess, and arterial oxygen saturation), and pain assessed by using numeric rating scale.

Interventions

DIAGNOSTIC_TESTperipheral lymphocytes subsets

The data were collected during the first and the second wave of epidemic in COVID-19 patients with acute respiratory distress syndrome. At the moment of hospitalization, at the moment of intensive care unit admission and during the in intensive care unit staying, the following data were collected: peripheral lymphocyte subsets were measured by multiple-color flow cytometry, chest computed tomography and ultrasonography scans (lung ultrasound score, diaphragmatic thickness and motion), arterial blood gas analysis parameters (pH, partial pressure of carbon dioxide, partial pressure of oxygen, concentration of hydrogen carbonate, base excess, and arterial oxygen saturation ), and pain assessed by using numeric rating scale. Macroscopic and microscopic hypopharynx and larynx damages were also evaluated by video-laryngoscopy and light miscoscopy.

Sponsors

San Salvatore Hospital of L'Aquila
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* COVID-19 patients * Acute respiratory distress syndrome * needing of ventilatory support

Exclusion criteria

* asymptomatic COVID-19 patients * few symptoms * mild symptoms * without needing of ventilatory support

Design outcomes

Primary

MeasureTime frameDescription
Peripheral lymphocyte subsetsChange from date of hospitalization until the date of hospital discharge or date of death from any cause, whichever came first, assessed at 60 weeksPeripheral lymphocyte subsets were measured by multiple-color flow cytometry,

Secondary

MeasureTime frameDescription
Chest computed tomographyFrom date of hospitalization until the date of hospital discharge or date of death from any cause, whichever came first, assessed every 10 days up to 60 weeksA chest computed tomography performed to assess lung damage
Chest ultrasonographyFrom date of hospitalization until the date of hospital discharge or date of death from any cause, whichever came first, assessed every day up to 60 weeksLung ultrasound score (sum of points in all 12 regions and ranges from 0 to 36; 0 points-presence of lung sliding with A lines or one or two isolated B lines; 1 point-moderate loss of lung aeration with three or four B lines (septal rockets); 2 points-severe loss of lung aeration with five or more B lines (glass rockets); and 3 points-presence of a hypoechoic poorly defined tissue characterized by consolidation)
Pain assessmentFrom date of hospitalization until the date of hospital discharge or date of death from any cause, whichever came first, assessed every day up to 60 weeksPain assessed by using numeric rating scale (the 11-point numeric scale ranges from '0' representing one pain extreme \[e.g. no pain\] to '10' representing the other pain extreme \[e.g. pain as bad as you can imagine or worst pain imaginable\])
Upper airway damagesFrom date of hospitalization until the date of hospital discharge or date of death from any cause, whichever came first, assessed every day up to 60 weeksMacroscopic and microscopic hypopharynx and larynx damages evaluated by video-laryngoscopy and light microscopy

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026